Latest News for TCRT
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) stock is surging on Tuesday with a massive session volume of 191.48 million compared to the average volume of 826.167 thousand, according to Benzinga Pro data.
Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension
Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie Velaris is the ninth company launched around Paragon-discovered assets and the first supported by Paragon's expanded leadership team BOSTON, Oct. 13, 2026 /PRNewswire/ -- Paragon Labs (together with related entities, "Paragon"), a biotechnology company focused on the…
Alaunos Therapeutics announces pricing of a public offering of common stock and pre-funded warrants to fund working capital and general corporate purposes.
Shares of Alaunos Therapeutics Inc (NASDAQ:TCRT) rose sharply in pre-market trading following a Securities and Exchange Commission filing that showed the company approved and adopted its Second Amended and Restated By-Laws, effective immediately.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TCRT.
U.S. House Trading
No House trades found for TCRT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.